TC BioPharm Receives European Patent Grant For Use Of Modified Gamma Delta Cells In Treating Cancer And Viral Indications
Portfolio Pulse from Benzinga Newsdesk
TC BioPharm has been granted a European patent for the use of modified gamma delta cells in treating cancer and viral indications. This development could enhance their therapeutic offerings and market position.
August 28, 2024 | 5:51 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
TC BioPharm has received a European patent for its modified gamma delta cells, which could strengthen its position in cancer and viral treatment markets.
The European patent grant is a significant milestone for TC BioPharm, as it provides intellectual property protection and could enhance their competitive edge in the biotech industry. This development is likely to positively impact their stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100